The earnings call reflected a strong financial performance with consistent operational revenue growth and strategic debt reduction. The company is focused on expanding its innovative portfolio, particularly in cardiovascular and ophthalmology sectors. While there are challenges related to the ARV generics supply chain and certain brand declines, the overall outlook remains positive with plans for shareholder value maximization and disciplined business development.

Company Guidance

During the Viatris Q3 2024 earnings call, the company provided guidance for the year, highlighting several key financial metrics. They reported total revenues of $3.8 billion, marking an operational revenue growth of approximately 3%, with adjusted EBITDA rising by 4% to $1.3 billion and adjusted EPS increasing by 6% to $0.75 per share. Free cash flow was reported at $866 million, excluding transaction costs and taxes. Additionally, Viatris repaid approximately $1.9 billion in debt, moving closer to their long-term gross leverage target. For 2025, the company anticipates continuing momentum in base business growth and aims to be more aggressive with share buybacks, leveraging their current valuation level. New product revenues were strong, with $133 million reported in the quarter, and the company expects to achieve the higher end of their $500 million to $600 million range for the year. Looking forward, Viatris reaffirmed their 2024 outlook, projecting base business operational revenue growth of approximately 2% and flat adjusted EBITDA and EPS compared to the previous year.

Consistent Operational Revenue Growth

Achieved sixth consecutive quarter of operational revenue growth with total revenues of $3.8 billion, representing approximately 3% growth.

Strong Financial Performance

Adjusted EBITDA grew by approximately 4% year-over-year, and adjusted EPS increased by approximately 6%.

Debt Reduction and Financial Strategy

Repaid approximately $1.9 billion in debt, focusing on achieving a long-term gross leverage target, and planning to return value to shareholders through dividends and share repurchases.

Expansion in Cardiovascular Portfolio

Entered an exclusive licensing agreement with Lexicon Pharmaceuticals for sotaliclosin, expanding the cardiovascular portfolio with approximately $2.5 billion in annual revenue.

New Product Revenue and Pipeline Growth

Delivered strong new product revenues of $133 million in the quarter, with a focus on further expanding the innovative pipeline, including ophthalmology and cardiovascular programs.

---

Viatris (DE:VIA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:VIA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 10, 2021	2021 (Q1)	0.77 / 0.89	0.866	2.33% (+0.02)	―	―
Aug 09, 2021	2021 (Q2)	0.84 / 0.94	1.068	-12.30% (-0.13)	―	―
Nov 08, 2021	2021 (Q3)	0.85 / 0.95	1.26	-24.73% (-0.31)	―	―
Feb 28, 2022	2021 (Q4)	0.79 / 0.77	0.729	5.66% (+0.04)	―	―
May 09, 2022	2022 (Q1)	0.79 / 0.89	0.886	0.43% (<+0.01)	―	―
Aug 08, 2022	2022 (Q2)	0.80 / 0.84	0.937	-10.44% (-0.10)	―	―
Nov 07, 2022	2022 (Q3)	0.80 / 0.84	0.948	-11.73% (-0.11)
Feb 27, 2023	2022 (Q4)	0.69 / 0.65	0.77	-16.06% (-0.12)
May 08, 2023	2023 (Q1)	0.66 / 0.74	0.89	-16.59% (-0.15)
Aug 07, 2023	2023 (Q2)	0.68 / 0.72	0.839	-14.06% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DE:VIA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2024	€10.87	€11.95	+9.99%
Aug 08, 2024	€10.24	€11.29	+10.30%
May 09, 2024	€10.78	€10.13	-6.00%
Feb 28, 2024	€11.78	€11.17	-5.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---